Swedbank AB Buys Shares of 90,900 NewAmsterdam Pharma Company N.V. $NAMS

Swedbank AB bought a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 90,900 shares of the company’s stock, valued at approximately $3,189,000. Swedbank AB owned approximately 0.08% of NewAmsterdam Pharma as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in NAMS. Capital World Investors grew its holdings in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after buying an additional 1,434,986 shares in the last quarter. Duquesne Family Office LLC grew its holdings in NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares in the last quarter. Wellington Management Group LLP grew its holdings in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after buying an additional 697,129 shares in the last quarter. Finally, Polar Capital Holdings Plc grew its holdings in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after buying an additional 393,855 shares in the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NAMS has been the subject of several analyst reports. Truist Financial initiated coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price for the company. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. Needham & Company LLC upped their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Guggenheim upped their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and an average price target of $48.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $36.56 on Thursday. The stock’s 50-day moving average is $33.16 and its two-hundred day moving average is $34.21. NewAmsterdam Pharma Company N.V. has a 1-year low of $16.78 and a 1-year high of $42.21. The company has a market cap of $4.27 billion, a price-to-earnings ratio of -20.42 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million for the quarter. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the sale, the insider owned 69,302 shares in the company, valued at $2,099,157.58. This represents a 59.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael H. Davidson sold 443,707 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer owned 174,144 shares in the company, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 881,512 shares of company stock worth $28,350,236 in the last quarter. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.